Can avatrombopag be taken regularly to treat platelets?

Avatrombopag (Avatrombopag), trade name Sucoxin, is a thrombopoietin receptor agonist mainly used to treat adult patients with thrombocytopenia associated with chronic liver disease.

The effect of avatrombopag usually begins to appear within 3 to 5 days after taking it, and the platelet count begins to increase, reaching a peak between 10 and 13 days, and then gradually decreases. This drug is designed to increase platelet levels before elective invasive tests or surgeries to reduce the risk of bleeding. Since its effects are short-term, long-term continued use is not recommended.

Avatrombopag may be associated with thrombosis and thromboembolic complications in patients with chronic liver disease. In addition, adverse reactions include fever, abdominal pain, nausea, headache, fatigue and peripheral edema. Therefore, long-term use without interruption may increase the risk of adverse effects.

According to the patient's condition and the doctor's advice, the taking period and dosage of avatrombopag vary. Generally speaking, it can only be taken orally for a maximum of 5 days, and the dose needs to be adjusted based on the platelet count. For patients who need long-term control of platelet levels, they should take it intermittently or choose other appropriate treatments under the guidance of a doctor.

For special groups such as pregnant women, the use of avatrombopag may cause harm to the fetus, so special caution should be taken. At the same time, patients with hepatic insufficiency also need to pay special attention when choosing drugs. Although avatrombopag is not metabolized by UGT and has no hepatotoxicity, it still needs to be taken according to the doctor's recommendations.